“We believe there is a vast opportunity for our products in Asia given that the regional palate is typically very predisposed to eating fish and fish-derived products. Our products can help millions of people who struggle with negative side effects or poor effect of traditional iron supplementation,” says Crawford Currie, Head of Medical R&D, in Hofseth BioCare.
This distribution agreement now provides HBC with a truly global access for the delivery of its nutritional and nutraceutical grade products.
DKSH’s activity is the market expansion, marketing and distribution of human & pharma grade raw materials through extensive local networks, market intelligence and formulation expertise. DKSH has the know-how to create unique recipes locally in a truly unparalleled way. Publicly listed on the SIX Swiss Exchange, the DKSH Group operates in 36 markets with 33,350 specialists, generating net sales of NOK 115 billion in 2019.
Thomas Sul, Co-Head Business Unit Performance Materials and Member of DKSH's Executive Committee comments: “The new partnership with HBC is a great match. DKSH gets access to the innovative, sustainable and science-based product range of Hofseth BioCare and they in turn access to our established customer base, our network of innovation centers and our in-depth industry knowledge. We are looking forward to a successful partnership with HBC.”
The agreement covers ten territories across Asia, including Thailand, Indonesia, Philippines, Malaysia, Vietnam, China, Japan, Korea, Taiwan and India. DKSH will also have the right to sell “white labelled” finished products across the territories on a non-exclusive basis as well.
The products included in the distribution agreement are:
“This is tremendous agreement for HBC and for the long-term growth of our business as we enter a partnership with one world’s longest established nutraceutical and pharmaceutical distributors across Asia for ingredients and finished products. The Asian market is a natural fit us given their natural enjoyment for fish. Also, yet again, this collaboration pays testament to the investments in R&D and science the company has made in the last 15 years in that we have “something different” to offer consumers,” says CEO of Hofseth BioCare, Roger Hofseth
The distribution contract with DKSH follows soon after the granting of a unique set of label claims for ProGo® in North America, centred around the prevention of iron deficiency anaemia.